New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 231-235

  Smith, Patrick F ^a,c   Petros, William P ^b   Soucie, Michael P ^b   Copeland, Kenneth R ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

End stage renal disease (ESRD); Enzyme mediated immunoassay technique (EMIT); Fluorescence polarization immunoassay (FPIA); High performance liquid chromatography (HPLC; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; DRUG CONTAMINATION; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FALSE POSITIVE REACTIONS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; VANCOMYCIN;

EID: 0031980142     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00016     Document Type: Article

References (22)

1. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27:594-8.
2. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995;28: 327-12.
3. Pryka RD. Vancomycin serum concentration monitoring: A continued debate. Ann Pharmacorher 1994;28:1397-9.
4. Zimmerman Z, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;15(1):85-91.
5. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96:119-26.
6. Follin SL, Mueller BA, Scott MS. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 1996;1:67-74.
7. Morse GD, Nairn DK, Bertino JS, Walshe JJ. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987;9:212-5.
8. Najjar TA, Al-Dhuwailie AA, Tekle A. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. J Chromatogr B 1995;672:295-9.
9. Anne L, Hu M, Chan K, Colin L, Gottwald K. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: Its detection in sera of renally impaired patients. Ther Drug Monit 1989;11:585-91.
10. White LO, Edwards R, Holt HA, Lovering A, Finch RG, Reeves DS. The in-vitro degradation at 37°C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimic Chemother 1988;22:739-45.
11. Hu MW, Anne L, Forni T, Gottwald K. Measurement of vancomycin in renally impaired patient samples using a new high-performance liquid chromatography method with vitamin B12 internal standard: comparison of HPLC, EMIT, and FPIA methods. Ther Drug Monit 1990;12:562-9.
12. Perino LM, Mueller BA. Accuracy of vancomycin serum concentrations in patients with renal failure. Ann Pharmacother 1993;27: 892-3.
13. Hortin GL, Landt M, Wilhite T, Smith CH. Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin. (letter) Clin Chem 1991;37:2009.
14. Morishige H, Shuto H, Ieiri I, Otsubo K, Oishi R. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. Ther Drug Monit 1996;18:80-5.
15. Marshall FJ. Structure studies on vancomycin. J Med Chem 1965; 8:18-22.
16. Aldwin L, Kabakoff DS. Metabolite interference in homogeneous enzyme immunoassay of phenytoin. Clin Chem 1981;27:770.
17. Matzke GR, Sawchuk RJ. Elevated serum phenytoin concentrations in a uremic patient when measured by enzyme-multiplied immunoassay. Drug Intell Clin Pharm 1981;15:386-8.
18. Sawchuk RJ, Matzke GR. Contribution of 5-(4-hydroxy-phenyl)-5-phenyl-hydantoin to the discrepancy between phenytoin analysis by EMIT and high-pressure liquid chromatography. Ther Drug Monit 1984;6:97-103.
19. Opheim KE, Ainardi V. Increase in apparent theophylline concentration in the serum of two uremic patients as measured by some immunoassay methods (caused by 1,3-dimethyluric acid). Clin Chem 1983;29:1698-9.
20. Bridges RR, Jennison TA. Spurious phenobarbital levels by fluorescence polarization immunoassay using TDx analyzer in patients with renal disease. Ther Drug Monit 1984;6:368-70.
21. Compton R, Lichti D. Influence of uremia on four assays for theophylline: Improved results with a monoclonal antibody in the TDx procedure. Clin Chem 1985;31:152-4.
22. Raisys VA. Determination of serum phenytoin in uremic and non-uremic patients using EMIT monoclonal assay. Clin Chem 1985; 31:931.